In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.
Where this comes from
- Record sourced from PubMed, PMID 36592466.
- Also identified by DOI 10.7326/J22-0105.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
GRADE Study Research Group; Nathan DM, Lachin JM, Buse JB, et al. <b>Glycemia reduction in type 2 diabetes-microvascular and cardiovascular outcomes.</b> N Engl J Med. 2022;387:1075-88. 36129997.
Medical subject headings
- Diabetes Mellitus, Type 2